HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME

/PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY) has initiated its global Phase 3 registrational trial, the TEMPO study, to...

Related Keywords

United States ,France ,Luis Sanay ,Kumar Budur ,Exchange Commission ,Zynerba Pharmaceuticals ,Prnewswire Harmony Biosciences Holdings Inc ,Drug Administration ,Paragon Biosciences ,Us Food Drug Administration ,Biosciences Holdings ,Orphan Drug Designation ,Chief Medical Officer ,Full Prescribing Information ,Harmony Biosciences ,Plymouth Meeting ,Private Securities Litigation Reform Act ,Annual Report ,Biosciences Media Contact ,Biosciences Investor Contact ,